Literature DB >> 24732241

Transcompartmental inflammatory responses in humans: IV versus endobronchial administration of endotoxin*.

Ronni R Plovsing1, Ronan M G Berg, Kevin A Evans, Lars Konge, Martin Iversen, Peter Garred, Kirsten Møller.   

Abstract

OBJECTIVES: Transcompartmental signaling during early inflammation may lead to propagation of disease to other organs. The time course and the mechanisms involved are still poorly understood. We aimed at comparing acute transcompartmental inflammatory responses in humans following lipopolysaccharide-induced pulmonary and systemic inflammation.
DESIGN: Randomized, double-blind, placebo-controlled, crossover study. SETTING ICU
SUBJECTS: Healthy male volunteers.
INTERVENTIONS: Fifteen volunteers (mean age, 23; SD, 2 yr) received Escherichia coli endotoxin (lipopolysaccharide, 4 ng/kg) IV or endobronchially on two different study days. Groups were evaluated by bronchoalveolar lavage at baseline (0 hr) and 2, 4, 6, 8, or 24 hours postchallenge. Cardiorespiratory variables were continuously recorded throughout the study day, and plasma and bronchoalveolar lavage fluid markers of inflammation were measured.
MEASUREMENTS AND MAIN RESULTS: IV endotoxin elicited a systemic inflammatory response with a time-dependent increase and peak in tumor necrosis factor-α, interleukin-6, and leukocyte counts (all p < 0.001). Furthermore, a delayed (6-8 hr) increase in bronchoalveolar lavage fluid interleukin-6 concentration (p < 0.001) and alveolar leukocyte count (p = 0.03) and a minor increase in bronchoalveolar lavage fluid tumor necrosis factor-α were observed (p = 0.06). Endobronchial endotoxin was followed by progressive alveolar neutrocytosis and increased bronchoalveolar lavage fluid tumor necrosis factor-α, interleukin-6, and albumin (all p < 0.001); a systemic inflammatory response was observed after 2-4 hours, with no change in plasma tumor necrosis factor-α.
CONCLUSIONS: Acute lung or systemic inflammation in humans is followed by a transcompartmental proinflammatory response, the degree and differential kinetics of which suggests that the propagation of inflammation may depend on the primary site of injury.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24732241     DOI: 10.1097/CCM.0000000000000320

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Exploring the boundaries of systemic inflammation*.

Authors:  Jason M Elinoff; Anthony F Suffredini
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

2.  Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of 'soluble CD163' in plasma.

Authors:  Anders Etzerodt; Ronan M G Berg; Ronni R Plovsing; Morten N Andersen; Magali Bebien; Mohamed Habbeddine; Toby Lawrence; Holger J Møller; Søren K Moestrup
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

3.  Reduced levels of pulmonary surfactant in COVID-19 ARDS.

Authors:  Peter Schousboe; Andreas Ronit; Henning B Nielsen; Thomas Benfield; Lothar Wiese; Nikolaos Scoutaris; Henrik Verder; Ronan M G Berg; Povl Verder; Ronni R Plovsing
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

4.  Dissociation between systemic and pulmonary anti-inflammatory effects of dexamethasone in humans.

Authors:  Johann Bartko; Leopold Stiebellehner; Ulla Derhaschnig; Christian Schoergenhofer; Michael Schwameis; Helmut Prosch; Bernd Jilma
Journal:  Br J Clin Pharmacol       Date:  2016-01-15       Impact factor: 4.335

5.  Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation.

Authors:  James N Fullerton; Elisabetta Segre; Roel P H De Maeyer; Alexander A N Maini; Derek W Gilroy
Journal:  J Vis Exp       Date:  2016-05-16       Impact factor: 1.355

6.  Compartmental immunophenotyping in COVID-19 ARDS: A case series.

Authors:  Andreas Ronit; Ronan M G Berg; Jakob T Bay; Anna K Haugaard; Magnus G Ahlström; Kristoffer S Burgdorf; Henrik Ullum; Sara B Rørvig; Klaus Tjelle; Nicolai B Foss; Thomas Benfield; Hanne Vibeke Marquart; Ronni R Plovsing
Journal:  J Allergy Clin Immunol       Date:  2020-10-23       Impact factor: 10.793

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.